Merit Medical SystemsFRA:MM3 +2.56%86 ROA % is 6.11% as of Mar. 2026, which is 103% above its 10-year median of 3.01. GuruFocus rates FRA:MM3 with a GF Score™ of 86/100 and a GF Value™ of €81.90 (Modestly Undervalued). Among 857 Medical Devices & Instruments companies, Merit Medical Systems ranks better than 71.06% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Merit Medical Systems's annualizedNet Income for the quarter that ended in Mar. 2026 was €142 Mil.
Merit Medical Systems's average Total Assets over the quarter that ended in Mar. 2026 was €2,323 Mil. Therefore, Merit Medical Systems's annualized ROA % for the quarter that ended in Mar. 2026 was 6.11%.
The historical rank and industry rank for Merit Medical Systems's ROA % or its related term are showing as below:
FRA:MM3'
s ROA % Range Over the Past 10 Years
Min: -0.58 Med: 3.01 Max: 5.32
Current: 5.32
During the past 13 years, Merit Medical Systems's highest ROA % was 5.32%. The lowest was -0.58%. And the median was 3.01%.
FRA:MM3's ROA % is ranked better than 71.06% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs FRA:MM3: 5.32
Merit Medical Systems (FRA:MM3) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Merit Medical Systems's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merit Medical Systems ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Merit Medical Systems's ROA % distribution charts can be found below:
* The bar in red indicates where Merit Medical Systems's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Merit Medical Systems (FRA:MM3) has a ROA % of 6.11% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Merit Medical Systems and its competitors. This is 103% above median its historical median of 3.01. According to the industry distribution chart, Merit Medical Systems ranks #248 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 28.9%.
Is Merit Medical Systems' ROA % too high?
Merit Medical Systems' current ROA % of 6.11% is 103% above median its 10-year median of 3.01. The Medical Devices & Instruments industry median ROA % is 0.59. Merit Medical Systems' value of 6.11% is 935.6% above this industry median. Based on the distribution chart, Merit Medical Systems ranks #248 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Merit Medical Systems has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Merit Medical Systems' ROA % compare to NVST and MMED?
According to the Medical Devices & Instruments industry distribution chart, Merit Medical Systems ranks #248 out of 857 companies for ROA %. This puts Merit Medical Systems in the upper half of its industry. The industry median ROA % is 0.59. Merit Medical Systems' value of 6.11% is 935.6% above this benchmark. While the company's 10-year median is 3.01 vs. the industry median of 0.59, Merit Medical Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merit Medical Systems's current ROA % of 6.11% is 935.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Merit Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merit Medical Systems's current ROA % is 6.11%, which is 103% above median its own 10-year median of 3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merit Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Merit Medical Systems (FRA:MM3) is currently considered Modestly Undervalued. The stock's GF Value™ is €81.90, compared to a current price of €60.00 — trading 26.7% below its estimated fair value. The current ROA % is 6.11%, which is 103% above median its 10-year median of 3.01 and 935.6% above the Medical Devices & Instruments industry median of 0.59. Merit Medical Systems' overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Merit Medical Systems (FRA:MM3), the current ROA % is 6.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merit Medical Systems (FRA:MM3) Overvalued in 2026?
Based on GuruFocus' analysis, Merit Medical Systems stock appears to be undervalued.
The current stock price of €60.00 is trading 26.7% below its estimated GF Value™ of €81.90.
GuruFocus considers Merit Medical Systems to be Modestly Undervalued.
Key valuation signals for FRA:MM3:
ROA %: 6.11% (103% above median its 10-year median of 3.01)
GF Value™: €81.90 vs. price of €60.00 (26.7% below fair value)
Industry Position: 935.6% above the Medical Devices & Instruments median (#248 of 857)
No single metric tells the full story. See the FRA:MM3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
86GF Score
Get the complete analysis for FRA:MM3
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MM3 has been successfully added to your 
